Digital health companies to benefit from unique market entry focused accelerator

20 September 2017

ANDHealth—Australia’s industry led, national accelerator for digital health technologies and 2016 recipient of the MTPConnect Project Fund Program—has announced the first cohort of six companies that will enter the ANDHealth Program.

ANDHealth’s unique model, led by a consortium of industry leaders with proven track records in commercialising digital health technologies in global markets, and supported MTPConnect, is focused on mid-stage technologies which will benefit from support and assistance in clinical and commercial validation to enhance their ability to penetrate global markets and/or raise significant growth capital.

ANDHealth Managing Director, Bronwyn Le Grice said: “There are many early stage accelerators in Australia that provide support for ideas and concepts behind innovative new companies. ANDHealth is different in that it brings a tailored support and advisory package for companies that already have a product, drawing on the deep knowledge and expertise of Australia’s own industry leaders who know what it takes to take a product from Australia to the world.”

ANDHealth’s first cohort of companies will benefit from a hands-on advisory group drawn from ANDHealth’s industry members, which include Novartis Pharmaceuticals, RMIT University, Planet Innovation, Curve Tomorrow, The Murdoch Children’s Research Institute, GP2U, HPM Executive, AusBiotech and HealthXL, that will work alongside each company to define and support a project which makes a significant contribution to their market readiness. In addition to the time and resources of the advisors, companies also can access $60,000 of project funds, media and communications support, intellectual property advice and access to a global network of digital health experts.

The quality of applications to participate in the first program was exceptionally high, with 55 mid-stage companies across the country seeking to accelerate the commercialisation of their digital health technologies.

“We had anticipated significant interest and demand, but were ultimately overwhelmed by the number and quality of applications, particularly given our focus on companies that are already well down the product development pathway. The exceptional quality of the first cohort of companies is a clear indication of the global potential of our digital health sector and we are delighted to be working with such innovative and dynamic teams,” said Le Grice.

The six successful participants are:

1. DoseMe – A precision medicine dosing platform which improves dosing accuracy and patient outcomes through real-time medication dosing decision support.
2. Human Gas Capsule – A connected electronic pill sensor which provides real time gas information for gut health diagnosis and management.
3. Perx – A digital intervention for changing the way people and healthcare organisations approach medication adherence which forms positive habits through fun games and memorable rewards.
4. Seer Medical – A wearable device and cloud computing technology which delivers hospital standard epilepsy monitoring and diagnosis in the home.
5. SkinView – A point of care solution for diagnosis of skin cancer and skin lesions which transforms a smartphone into a diagnostic dermatoscope.
6. PenPal – A digital allergy tool which empowers temporary carers of children with allergies through on the spot access to life saving personalised information and treatment steps.